Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Aug;48(2):167–175. doi: 10.1038/bjc.1983.172

Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here?

K D Bagshawe
PMCID: PMC2011455  PMID: 6192836

Abstract

An overview of the application of markers for solid tumours is presented. Some of the potential problems with general cancer tests are considered as well as the ways in which the more specific markers have been applied. The limited specificities of markers defined so far remain a serious limitation but they have found useful clinical application. Their use in radioimmunolocalisation provides an interesting challenge to the physical methods of tumour localisation and the possibilities of drug targeting by antibodies are as exciting as the difficulties are formidable. It is, I suggest, a field that will continue to evolve and be productive.

Full text

PDF
167

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BAGSHAWE K. D., BROOKS W. D. Subacute pulmonary hypertension due to chorionepithelioma. Lancet. 1959 Mar 28;1(7074):653–658. doi: 10.1016/s0140-6736(59)92402-x. [DOI] [PubMed] [Google Scholar]
  2. Bagshawe K. D., Harland S. Immunodiagnosis and monitoring of gonadotrophin-producing metastases in the central nervous system. Cancer. 1976 Jul;38(1):112–118. doi: 10.1002/1097-0142(197607)38:1<112::aid-cncr2820380120>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  3. Bagshawe K. D. Recent observations related to the chemotherapy and immunology of gestational choriocarcinoma. Adv Cancer Res. 1973;18:231–263. doi: 10.1016/s0065-230x(08)60754-x. [DOI] [PubMed] [Google Scholar]
  4. Bagshawe K. D. Risk and prognostic factors in trophoblastic neoplasia. Cancer. 1976 Sep;38(3):1373–1385. doi: 10.1002/1097-0142(197609)38:3<1373::aid-cncr2820380342>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  5. Bagshawe K. D., Wilson H., Dublon P., Smith A., Baldwin M., Kardana A. Follow-up after hydatidiform mole: studies using radioimmunoassay for urinary human chorionic gonadotrophin (HCG). J Obstet Gynaecol Br Commonw. 1973 May;80(5):461–468. doi: 10.1111/j.1471-0528.1973.tb15962.x. [DOI] [PubMed] [Google Scholar]
  6. Balding P., Light P. A., Preece A. W. Response of human lymphocytes to PHA and tumour-associated antigens as detected by fluorescence polarization. Br J Cancer. 1980 Jan;41(1):73–85. doi: 10.1038/bjc.1980.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Begent R. H., Keep P. A., Green A. J., Searle F., Bagshawe K. D., Jewkes R. F., Jones B. E., Barratt G. M., Ryman B. E. Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody. Lancet. 1982 Oct 2;2(8301):739–742. doi: 10.1016/s0140-6736(82)90923-0. [DOI] [PubMed] [Google Scholar]
  8. Biquard J. M., Aupoix M. 5-Bromodeoxyuridine induces expression of a tumour-specific surface antigen on normal avian cells. Nature. 1978 Mar 16;272(5650):284–286. doi: 10.1038/272284a0. [DOI] [PubMed] [Google Scholar]
  9. Bloomer W. D., McLaughlin W. H., Neirinckx R. D., Adelstein S. J., Gordon P. R., Ruth T. J., Wolf A. P. Astatine-211--tellurium radiocolloid cures experimental malignant ascites. Science. 1981 Apr 17;212(4492):340–341. doi: 10.1126/science.7209534. [DOI] [PubMed] [Google Scholar]
  10. Bogoch S., Bogoch E. S. Disarmed anti-malignin antibody in human cancer. Lancet. 1979 May 5;1(8123):987–987. doi: 10.1016/s0140-6736(79)91776-8. [DOI] [PubMed] [Google Scholar]
  11. Browne P., Bagshawe K. D. Enhancement of human chorionic gonadotrophin production by antimetabolites. Br J Cancer. 1982 Jul;46(1):22–29. doi: 10.1038/bjc.1982.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cercek L., Cercek B. Application of the phenomenon of changes in the structuredness of cytoplasmic matrix (SCM) in the diagnosis of malignant disorders: a review. Eur J Cancer. 1977 Sep;13(9):903–915. doi: 10.1016/0014-2964(77)90166-9. [DOI] [PubMed] [Google Scholar]
  13. Dullens H. F., De Weger R. A., Vennegoor C., Den Otter W. Anti-tumour effect of chlorambucil-antibody complexes in a murine melanoma system. Eur J Cancer. 1979 Jan;15(1):69–75. doi: 10.1016/0014-2964(79)90207-x. [DOI] [PubMed] [Google Scholar]
  14. Dykes P. W., Hine K. R., Bradwell A. R., Blackburn J. C., Reeder T. A., Drolc Z., Booth S. N. Localisation of tumour deposits by external scanning after injection of radiolabelled anti-carcinoembryonic antigen. Br Med J. 1980 Jan 26;280(6209):220–222. doi: 10.1136/bmj.280.6209.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Epenetos A. A., Britton K. E., Mather S., Shepherd J., Granowska M., Taylor-Papadimitriou J., Nimmon C. C., Durbin H., Hawkins L. R., Malpas J. S. Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet. 1982 Nov 6;2(8306):999–1005. doi: 10.1016/s0140-6736(82)90046-0. [DOI] [PubMed] [Google Scholar]
  16. Ettinger D. S., Order S. E., Wharam M. D., Parker M. K., Klein J. L., Leichner P. K. Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer. Cancer Treat Rep. 1982 Feb;66(2):289–297. [PubMed] [Google Scholar]
  17. Farrands P. A., Perkins A. C., Pimm M. V., Embleton M. J., Hardy J. D., Baldwin R. W., Hardcastle J. D. Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody. Lancet. 1982 Aug 21;2(8295):397–400. doi: 10.1016/s0140-6736(82)90437-8. [DOI] [PubMed] [Google Scholar]
  18. Field E. J., Caspary E. A. Lymphocyte sensitisation: an in-vitro test for cancer? Lancet. 1970 Dec 26;2(7687):1337–1341. doi: 10.1016/s0140-6736(70)92361-5. [DOI] [PubMed] [Google Scholar]
  19. Germa-Lluch J. R., Begent R. H., Bagshawe K. D. Tumour-marker levels and prognosis in malignant teratoma of the testis. Br J Cancer. 1980 Dec;42(6):850–855. doi: 10.1038/bjc.1980.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ghose T., Norvell S. T., Guclu A., Cameron D., Bodurtha A., MacDonald A. S. Immunochemotherapy of cancer with chlorambucil-carrying antibody. Br Med J. 1972 Aug 26;3(5825):495–499. doi: 10.1136/bmj.3.5825.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Glennie M. J., Stevenson G. T. Univalent antibodies kill tumour cells in vitro and in vivo. Nature. 1982 Feb 25;295(5851):712–714. doi: 10.1038/295712a0. [DOI] [PubMed] [Google Scholar]
  22. Goldenberg D. M., DeLand F., Kim E., Bennett S., Primus F. J., van Nagell J. R., Jr, Estes N., DeSimone P., Rayburn P. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978 Jun 22;298(25):1384–1386. doi: 10.1056/NEJM197806222982503. [DOI] [PubMed] [Google Scholar]
  23. Gray B. N., Walker C., Barnard R., Bennett R. C. Tennessee antigen: its value in the monitoring of patients with colorectal cancer. Dis Colon Rectum. 1982 Sep;25(6):542–544. doi: 10.1007/BF02564163. [DOI] [PubMed] [Google Scholar]
  24. HERTZ R., BERGENSTAL D. M., LIPSETT M. B., PRICE E. B., HILBISH T. F. Chemotherapy of choriocarcinoma and related trophoblastic tumors in women. J Am Med Assoc. 1958 Oct 18;168(7):845–854. doi: 10.1001/jama.1958.03000070001001. [DOI] [PubMed] [Google Scholar]
  25. Herberman R. B. Immunologic tests in diagnosis of cancer. Am J Clin Pathol. 1977 Nov;68(5 Suppl):688–698. [PubMed] [Google Scholar]
  26. Herlyn D. M., Steplewski Z., Herlyn M. F., Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 1980 Mar;40(3):717–721. [PubMed] [Google Scholar]
  27. Hoffmann E. J., Phelps M. E., Mullani N. A., Higgins C. S., Ter-Pogossian M. M. Design and performance characteristics of a whole-body positron transaxial tomograph. J Nucl Med. 1976 Jun;17(6):493–502. [PubMed] [Google Scholar]
  28. Larson S. M., Brown J. P., Wright P. W., Carrasquillo J. A., Hellström I., Hellström K. E. Imaging of melanoma with L-131-labeled monoclonal antibodies. J Nucl Med. 1983 Feb;24(2):123–129. [PubMed] [Google Scholar]
  29. Lewis A. J., Daily N. H., Ayre J. E. The serologic detection of cancer by immunodiffusion. The Lewis test. Oncology. 1971;25(1):33–43. doi: 10.1159/000224551. [DOI] [PubMed] [Google Scholar]
  30. Lewis J. C., Bagshawe K. D., Keep P. A. The distribution of parenterally administered antibody to CEA in colorectal xenografts. Preliminary findings. Oncodev Biol Med. 1982;3(2-3):161–168. [PubMed] [Google Scholar]
  31. Lewis J. C., Keep P. A. Relationship of serum CEA levels to tumour size and CEA content in nude mice bearing colonic-tumour xenografts. Br J Cancer. 1981 Sep;44(3):381–387. doi: 10.1038/bjc.1981.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. MAKARI J. G. Use of Schultz-Dale test for detection of specific antigen in sera of patients with carcinoma. Br Med J. 1955 Nov 26;2(4951):1291–1295. doi: 10.1136/bmj.2.4951.1291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Mach J. P., Carrel S., Forni M., Ritschard J., Donath A., Alberto P. Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. N Engl J Med. 1980 Jul 3;303(1):5–10. doi: 10.1056/NEJM198007033030102. [DOI] [PubMed] [Google Scholar]
  34. Menendez-Botet C. J., Oettgen H. F., Pinsky C. M., Schwartz M. K. A preliminary evaluation of tissue polypeptide antigen in serum or urine (or both) of patients with cancer or benign neoplasms. Clin Chem. 1978 Jun;24(6):868–872. [PubMed] [Google Scholar]
  35. Mitchell H., Wood P., Pentycross C. R., Abel E., Bagshawe K. D. The SCM test for cancer. an evaluation in terms of lymphocytes from healthy donors and cancer patients. Br J Cancer. 1980 May;41(5):772–777. doi: 10.1038/bjc.1980.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Newlands E. S., Begent R. H., Rustin G. J., Parker D., Bagshawe K. D. Further advances in the management of malignant teratomas of the testis and other sites. Lancet. 1983 Apr 30;1(8331):948–951. doi: 10.1016/s0140-6736(83)92079-2. [DOI] [PubMed] [Google Scholar]
  37. PRESSMAN D., KORNGOLD L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer. 1953 May;6(3):619–623. doi: 10.1002/1097-0142(195305)6:3<619::aid-cncr2820060319>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  38. Pentycross C. R. The Tennessee antigen test. An evaluation in cancer and non-cancer patients and normal subjects. Br J Cancer. 1982 Feb;45(2):223–229. doi: 10.1038/bjc.1982.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Primus F. J., Wang R. H., Goldenberg D. M., Hansen H. J. Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoembryonic antigen. Cancer Res. 1973 Nov;33(11):2977–2982. [PubMed] [Google Scholar]
  40. Pritchard J. A., Moore J. L., Sutherland W. H., Joslin C. A. Macrophage-electrophoretic-mobility (M.E.M.) test for malignant disease. An independent confirmation. Lancet. 1972 Sep 23;2(7778):627–629. doi: 10.1016/s0140-6736(72)93018-8. [DOI] [PubMed] [Google Scholar]
  41. Pritchard J. A., Sutherland W. H., Seaman J. E., Deeley T. J., Evans I. H., Kerby I. J., James K. W., Paterson I. C. Cancer-specific density changes in lymphocytes after stimulation with phytohaemagglutinin. Lancet. 1978 Dec 16;2(8103):1275–1277. doi: 10.1016/s0140-6736(78)92039-1. [DOI] [PubMed] [Google Scholar]
  42. Quinones J., Mizejewski G., Beierwaltes W. H. Choriocarcinoma scanning using radiolabeled anti-body to chorionic gonadotrophin. J Nucl Med. 1971 Feb;12(2):69–75. [PubMed] [Google Scholar]
  43. Raso V. Antibody mediated delivery of toxic molecules to antigen bearing target cells. Immunol Rev. 1982;62:93–117. doi: 10.1111/j.1600-065x.1982.tb00391.x. [DOI] [PubMed] [Google Scholar]
  44. Rowland G. F., O'Neill G. J., Davies D. A. Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage. Nature. 1975 Jun 5;255(5508):487–488. doi: 10.1038/255487a0. [DOI] [PubMed] [Google Scholar]
  45. Searle F., Boden J., Lewis J. C., Bagshawe K. D. A human choriocarcinoma xenograft in nude mice; a model for the study of antibody localization. Br J Cancer. 1981 Aug;44(2):137–144. doi: 10.1038/bjc.1981.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Sears H. F., Atkinson B., Mattis J., Ernst C., Herlyn D., Steplewski Z., Häyry P., Koprowski H. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet. 1982 Apr 3;1(8275):762–765. doi: 10.1016/s0140-6736(82)91811-6. [DOI] [PubMed] [Google Scholar]
  47. Smith F. W. Whole body nuclear magnetic resonance imaging. Radiography. 1981 Dec;47(564):297–300. [PubMed] [Google Scholar]
  48. Tal C., Halperin M. Presence of serologically distinct protein in serum of cancer patients and pregnant women. An attempt to develop a diagnostic cancer test. Isr J Med Sci. 1970 Nov-Dec;6(6):708–716. [PubMed] [Google Scholar]
  49. Tee D. E., Munson K. W. Modified Makari skin test in follow-up of bladder-cancer patients. Lancet. 1977 Sep 3;2(8036):480–481. doi: 10.1016/s0140-6736(77)91604-x. [DOI] [PubMed] [Google Scholar]
  50. Watanabe A., Nagashima H. Altered dynamics of alpha-fetoprotein production following pyridoxine and adenosine 5'-triphosphate administration to cirrhotic patients with or without primary hepatomas and to liver-injured and hepatoma-bearing rats. Oncodev Biol Med. 1981;2(5):313–321. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES